Adavosertib Before Surgery for Ovarian Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This pilot early phase I trial studies how adavosertib affects the tumor deoxyribonucleic acid (DNA) of patients undergoing surgery for high grade (fast growing or aggressive) ovarian, fallopian tube, or primary peritoneal cancer that has spread to other places in the body (advanced). Certain characteristics in the DNA of these patients may affect how well they respond to treatment. Learning how adavosertib affects DNA in tumor cells may help doctors plan effective treatment.
Will I have to stop taking my current medications?
The trial requires stopping certain medications, especially those affecting liver enzymes like CYP3A4 and P-glycoprotein, two weeks before starting and during the study. Herbal supplements and statins like atorvastatin are also not allowed. It's best to discuss your current medications with the trial team to see if any need to be paused.
Is Adavosertib safe for humans?
What makes the drug Adavosertib unique for ovarian cancer treatment?
What data supports the effectiveness of the drug Adavosertib before surgery for ovarian cancer?
Research shows that Adavosertib, when combined with chemotherapy, can enhance the effectiveness of treatment in ovarian cancer, especially in cases where the cancer is resistant to platinum-based drugs. It has been found to work well with other chemotherapy drugs, making cancer cells more sensitive to treatment.12378
Who Is on the Research Team?
Shannon Westin, MD
Principal Investigator
M.D. Anderson Cancer Center
Are You a Good Fit for This Trial?
This trial is for women with advanced high-grade ovarian, fallopian tube, or primary peritoneal cancer who haven't had prior treatment for these conditions. Participants must be able to swallow pills, use effective contraception if of childbearing potential, and have no gastrointestinal issues affecting medication absorption. They should understand the study and consent to it, meet certain health criteria including an ECOG status of 0 or 1, and be scheduled for surgery within a specific timeframe.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive adavosertib orally once daily on days 1-5, with potential additional cycles on days 8-12, 15-19, and 22-26, followed by standard of care laparoscopy
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Adavosertib
Find a Clinic Near You
Who Is Running the Clinical Trial?
M.D. Anderson Cancer Center
Lead Sponsor
National Cancer Institute (NCI)
Collaborator